Benoît Guérette

Suggest Changes
Learn More
OBJECTIVE To assess the efficacy and safety of adalimumab plus methotrexate (ADA+MTX) compared with methotrexate monotherapy in achieving stable low disease activity (LDA; disease activity score(More)
BACKGROUND Adalimumab is an effective treatment for chronic plaque psoriasis. OBJECTIVE To evaluate the safety and efficacy of adalimumab for psoriasis patients who did not adequately respond to(More)
OBJECTIVE To evaluate open-label adalimumab therapy for clinical effectiveness, fistula healing, patient-reported outcomes and safety in Canadian patients with moderate to severe Crohn's disease (CD)(More)
OBJECTIVE To evaluate the effectiveness and safety of adalimumab in patients with active psoriatic arthritis (PsA) and an inadequate response to prior therapy. METHODS Patients were treated with(More)
BACKGROUND This multicenter, open-label, prospective, single cohort study evaluated the effectiveness and safety of adalimumab in a clinical setting reflecting the Canadian standard of care for the(More)
OBJECTIVES To compare responses in patients with early rheumatoid arthritis (RA) initially treated with the tumour necrosis factor inhibitor (TNFi) adalimumab+methotrexate (MTX) versus MTX(More)
OBJECTIVE Rheumatoid arthritis (RA) treatment recommendations suggest target attainment within the first 3 months of therapy, yet delayed clinical responses can occur. This analysis assessed the(More)